WHO Head Reiterates Call for Two-Month COVID-19 Booster Moratorium
Director-General Tedros Adhanom Ghebreyesus is concerned booster shots could limit supply for countries struggling to get first and second vaccine doses.
World Health Organization (WHO) Director-General Tedros Adlhanom Ghebreyesus stated to reporters in Budapest, Hungary on August 23rd, 2021 that he wanted countries considering third vaccine doses “to share what can be used for boosters with other countries so [they] can increase their first and second vaccination coverage,” according to a report from the Associated Press.
Earlier in August, Adlhanom Ghebreyesus had called for a two-month moratorium on COVID-19 booster shots (1).
Various countries, including the United States and Israel, have either begun offering or plan to offer third vaccine doses. Hungary recently became the first European Union member state to allow residents to sign up for a booster shot. Currently, more than 187,000 Hungarian residents have received the booster.
Vaccine inequality was a point of emphasis for Adlhanom Ghebreyesus. He stated that while 4.8 billion vaccine doses have been delivered globally, 75% of these shots have gone to just 10 countries. Conversely, vaccine coverage across Africa is at less than 2%.
“The virus will get the chance to circulate in countries with low vaccination coverage, and the delta variant could evolve to become more virulent, and at the same time more potent variants could also emerge,” said Adlhanom Ghebreyesus in the news report.
Source: Associated Press
1. Branswell, Helen. WHO calls for a temporary moratorium on administering booster shots of Covid-19 vaccines. STAT, Aug 4. 2021, retrieved from https://www.statnews.com/2021/08/04/who-calls-for-a-temporary-moratorium-on-administering-booster-shots-of-covid-19-vaccines/
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
